Cantor Fitzgerald Reiterates Overweight on Mirum Pharmaceuticals, Maintains $35 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and maintained a $35 price target.
February 29, 2024 | 6:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald maintains an Overweight rating and a $35 price target on Mirum Pharmaceuticals.
The reiteration of an Overweight rating and maintenance of a $35 price target by a reputable analyst like Josh Schimmer suggests a positive outlook for Mirum Pharmaceuticals. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90